These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25997113)

  • 1. Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.
    Dick LW; Mehl JT; Loughney JW; Mach A; Rustandi RR; Ha S; Zhang L; Przysiecki CT; Dieter L; Hoang VM
    Hum Vaccin Immunother; 2015; 11(6):1518-25. PubMed ID: 25997113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
    Masforrol Y; Gil J; García D; Noda J; Ramos Y; Betancourt L; Guirola O; González S; Acevedo B; Besada V; Reyes O; González LJ
    Hum Vaccin Immunother; 2017 Nov; 13(11):2548-2560. PubMed ID: 29083947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.
    Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX
    Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens.
    Gil J; Betancourt LZ; Sardiñas G; Yero D; Niebla O; Delgado M; García D; Pajón R; Sánchez A; González LJ; Padrón G; Campa C; Sotolongo F; Barberó R; Guillén G; Herrera L; Besada V
    Hum Vaccin; 2009 May; 5(5):347-56. PubMed ID: 19377283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
    Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
    Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.
    Poolman JT; Richmond P
    Expert Rev Vaccines; 2015; 14(9):1277-87. PubMed ID: 26204792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.
    Williams JN; Skipp PJ; Humphries HE; Christodoulides M; O'Connor CD; Heckels JE
    Infect Immun; 2007 Mar; 75(3):1364-72. PubMed ID: 17158897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of surface protein antigens, PorA and PorB, in Bexsero vaccine using quantitative mass spectrometry.
    Whiting G; Vipond C; Facchetti A; Chan H; Wheeler JX
    Vaccine; 2020 Feb; 38(6):1431-1435. PubMed ID: 31839469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine.
    Tani C; Stella M; Donnarumma D; Biagini M; Parente P; Vadi A; Magagnoli C; Costantino P; Rigat F; Norais N
    Vaccine; 2014 Mar; 32(11):1273-9. PubMed ID: 24462403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.
    Tsolakos N; Lie K; Bolstad K; Maslen S; Kristiansen PA; Høiby EA; Wallington A; Vipond C; Skehel M; Tang CM; Feavers IM; Wedege E; Wheeler JX
    Vaccine; 2010 Apr; 28(18):3211-8. PubMed ID: 20188677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by design approach in the development of an ultra-high-performance liquid chromatography method for Bexsero meningococcal group B vaccine.
    Nompari L; Orlandini S; Pasquini B; Campa C; Rovini M; Del Bubba M; Furlanetto S
    Talanta; 2018 Feb; 178():552-562. PubMed ID: 29136861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress of serogroup B meningococcal outer membrane vesicle vaccines].
    Yue MM; Xu J; Xu L; Shao ZJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Sep; 56(9):1333-1340. PubMed ID: 36207900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.